The last canonical/non-canonical dual modulator discussed is compound 18 (Hiroshima International University), a novel dual partial agonist of FXR and PPARγ providing strong mechanistic synergy for T2DM-induced NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.